Pharmacogenomics and Patient Care: One Size Does Not Fit All

Overview

Journal Sci Transl Med

Specialties General Medicine
Science

Date 2012 Sep 29

PMID 23019654

Citations 28

Authors

Kathleen M Giacomini

Sook Wah Yee

Mark J Ratain

Richard M Weinshilboum

Naoyuki Kamatani

Yusuke Nakamura

Affiliations

Soon will be listed here.

Abstract

The time is ripe to assess whether pharmacogenomics research--the study of the genetic basis for variation in drug response--has provided important insights into a personalized approach to prescribing and dosing medications. Here, we describe the status of the field and approaches for addressing some of the open questions in pharmacogenomics research and use of genetic testing in guiding drug therapy.

Citing Articles

A review of precision medicine in developing pharmaceutical products: Perspectives and opportunities.

Martinez-Jimenez J, Sathisaran I, Reyes Figueroa F, Reyes S, Lopez-Nieves M, Vlaar C Int J Pharm. 2024; 670:125070.

PMID: 39689830 PMC: 11781955. DOI: 10.1016/j.ijpharm.2024.125070.

Trend of pharmaceuticals 3D printing in the Middle East and North Africa (MENA) region: An overview, regulatory perspective and future outlook.

Alzhrani R, Alyahya M, Algahtani M, Fitaihi R, Tawfik E Saudi Pharm J. 2024; 32(6):102098.

PMID: 38774811 PMC: 11107368. DOI: 10.1016/j.jsps.2024.102098.

Opportunities and challenges of 5G network technology toward precision medicine.

Kang C, Lee T, Lim W, Yeo W Clin Transl Sci. 2023; 16(11):2078-2094.

PMID: 37702288 PMC: 10651640. DOI: 10.1111/cts.13640.

Deciphering genetic causes for sex differences in human health through drug metabolism and transporter genes.

Huang Y, Shan Y, Zhang W, Lee A, Li F, Stranger B Nat Commun. 2023; 14(1):175.

PMID: 36635277 PMC: 9837057. DOI: 10.1038/s41467-023-35808-6.

Recent Advances in Cancer Drug Discovery Through the Use of Phenotypic Reporter Systems, Connectivity Mapping, and Pooled CRISPR Screening.

Salame N, Fooks K, El-Hachem N, Bikorimana J, Mercier F, Rafei M Front Pharmacol. 2022; 13:852143.

PMID: 35795568 PMC: 9250974. DOI: 10.3389/fphar.2022.852143.

References

Regan M, Leyland-Jones B, Bouzyk M, Pagani O, Tang W, Kammler R . CYP2D6 genotype and tamoxifen response in postmenopausal women with endocrine-responsive breast cancer: the breast international group 1-98 trial. J Natl Cancer Inst. 2012; 104(6):441-51. PMC: 3309132. DOI: 10.1093/jnci/djs125. View

Zhou K, Bellenguez C, Spencer C, Bennett A, Coleman R, Tavendale R . Common variants near ATM are associated with glycemic response to metformin in type 2 diabetes. Nat Genet. 2010; 43(2):117-20. PMC: 3030919. DOI: 10.1038/ng.735. View

Ozeki T, Mushiroda T, Yowang A, Takahashi A, Kubo M, Shirakata Y . Genome-wide association study identifies HLA-A*3101 allele as a genetic risk factor for carbamazepine-induced cutaneous adverse drug reactions in Japanese population. Hum Mol Genet. 2010; 20(5):1034-41. DOI: 10.1093/hmg/ddq537. View

Hindorff L, Sethupathy P, Junkins H, Ramos E, Mehta J, Collins F . Potential etiologic and functional implications of genome-wide association loci for human diseases and traits. Proc Natl Acad Sci U S A. 2009; 106(23):9362-7. PMC: 2687147. DOI: 10.1073/pnas.0903103106. View

Lennard L, VAN LOON J, Weinshilboum R . Pharmacogenetics of acute azathioprine toxicity: relationship to thiopurine methyltransferase genetic polymorphism. Clin Pharmacol Ther. 1989; 46(2):149-54. DOI: 10.1038/clpt.1989.119. View

Kangelaris K, Bent S, Nussbaum R, Garcia D, Tice J . Genetic testing before anticoagulation? A systematic review of pharmacogenetic dosing of warfarin. J Gen Intern Med. 2009; 24(5):656-64. PMC: 2669873. DOI: 10.1007/s11606-009-0949-1. View

Agarwal S, Hachamovitch R, Menon V . Current trial-associated outcomes with warfarin in prevention of stroke in patients with nonvalvular atrial fibrillation: a meta-analysis. Arch Intern Med. 2012; 172(8):623-31. DOI: 10.1001/archinternmed.2012.121. View

Cooper G, Johnson J, Langaee T, Feng H, Stanaway I, Schwarz U . A genome-wide scan for common genetic variants with a large influence on warfarin maintenance dose. Blood. 2008; 112(4):1022-7. PMC: 2515139. DOI: 10.1182/blood-2008-01-134247. View

Gage B, Eby C, Johnson J, Deych E, Rieder M, Ridker P . Use of pharmacogenetic and clinical factors to predict the therapeutic dose of warfarin. Clin Pharmacol Ther. 2008; 84(3):326-31. PMC: 2683977. DOI: 10.1038/clpt.2008.10. View

10.

Flockhart D, Gage B, Gandolfi R, King R, Lyon E, Nussbaum R . Pharmacogenetic testing of CYP2C9 and VKORC1 alleles for warfarin. Genet Med. 2008; 10(2):139-50. DOI: 10.1097/GIM.0b013e318163c35f. View

11.

Daly A, Donaldson P, Bhatnagar P, Shen Y, Peer I, Floratos A . HLA-B*5701 genotype is a major determinant of drug-induced liver injury due to flucloxacillin. Nat Genet. 2009; 41(7):816-9. DOI: 10.1038/ng.379. View

12.

Shuldiner A, OConnell J, Bliden K, Gandhi A, Ryan K, Horenstein R . Association of cytochrome P450 2C19 genotype with the antiplatelet effect and clinical efficacy of clopidogrel therapy. JAMA. 2009; 302(8):849-57. PMC: 3641569. DOI: 10.1001/jama.2009.1232. View

13.

Aberg K, Adkins D, Bukszar J, Webb B, Caroff S, Miller D . Genomewide association study of movement-related adverse antipsychotic effects. Biol Psychiatry. 2009; 67(3):279-82. PMC: 3388725. DOI: 10.1016/j.biopsych.2009.08.036. View

14.

Kaiser J . Clinical medicine. Biomarker tests need closer scrutiny, IOM concludes. Science. 2012; 335(6076):1554. DOI: 10.1126/science.335.6076.1554. View

15.

McCormack M, Alfirevic A, Bourgeois S, Farrell J, Kasperaviciute D, Carrington M . HLA-A*3101 and carbamazepine-induced hypersensitivity reactions in Europeans. N Engl J Med. 2011; 364(12):1134-43. PMC: 3113609. DOI: 10.1056/NEJMoa1013297. View

16.

Tanaka Y, Kurosaki M, Nishida N, Sugiyama M, Matsuura K, Sakamoto N . Genome-wide association study identified ITPA/DDRGK1 variants reflecting thrombocytopenia in pegylated interferon and ribavirin therapy for chronic hepatitis C. Hum Mol Genet. 2011; 20(17):3507-16. DOI: 10.1093/hmg/ddr249. View

17.

Iyer L, Das S, Janisch L, Wen M, Ramirez J, Karrison T . UGT1A1*28 polymorphism as a determinant of irinotecan disposition and toxicity. Pharmacogenomics J. 2002; 2(1):43-7. DOI: 10.1038/sj.tpj.6500072. View

18.

Mallal S, Phillips E, Carosi G, Molina J, Workman C, Tomazic J . HLA-B*5701 screening for hypersensitivity to abacavir. N Engl J Med. 2008; 358(6):568-79. DOI: 10.1056/NEJMoa0706135. View

19.

Liu T, Altman R . Using multiple microenvironments to find similar ligand-binding sites: application to kinase inhibitor binding. PLoS Comput Biol. 2012; 7(12):e1002326. PMC: 3248393. DOI: 10.1371/journal.pcbi.1002326. View

20.

Tatonetti N, Ye P, Daneshjou R, Altman R . Data-driven prediction of drug effects and interactions. Sci Transl Med. 2012; 4(125):125ra31. PMC: 3382018. DOI: 10.1126/scitranslmed.3003377. View